... ENG

SABCS 2022

ESMO 2022

ASCO 2022

CLINICAL IMPACT Series

AI Series

AACR 2022

COVID Impact

OICR Series

SABCS 2021

ESMO 2021

ASCO 2021

SABCS 2020

SABCS 2019

ESMO 2019

Trans-aTTom: To offer more?

Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen.

Trans-aTTom: To offer more?

ST.GALLEN 2019

Editorial board introductions

Processes in cancer

All Editorial Videos

Trans-aTTom: To offer more?

Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen.

Trans-aTTom: To offer more?